Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SHR-A1403

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Hengrui Pharma

Drug class:

Microtubule inhibitor, c-MET-targeted antibody-drug conjugate

Related drugs:

‹

HRA00129-C004 (3)

REGN5093-M114 (3)

ado-trastuzumab emtansine (97)

eribulin mesylate (47)

brentuximab vedotin (29)

disitamab vedotin (27)

mirvetuximab soravtansine-gynx (16)

enfortumab vedotin-ejfv (14)

cabazitaxel (12)

ixabepilone (6)

LR004-VC-MMAE (5)

PF-06804103 (4)

belantamab mafodotin-blmf (3)

polatuzumab vedotin-piiq (3)

RGX-019-MMAE (3)

BAY 94-9343 (3)

IMAB027-vcMMAE (2)

PF-06650808 (2)

MF-TTZ-MMAE (1)

PF-06263507 (1)

PF-08046054 (1)

tisotumab vedotin-tftv (1)

estramustine (0)

Nectin-4 ADC (0)

vintafolide (0)

HuMax-AXL-ADC (0)

mebendazole (0)

HRA00129-C004 (3)

REGN5093-M114 (3)

›

MET overexpression	Hepatocellular Cancer	MET overexpression	Hepatocellular Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D
MET overexpression	Pancreatic Cancer	MET overexpression	Pancreatic Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D
MET overexpression	Non Small Cell Lung Cancer	MET overexpression	Non Small Cell Lung Cancer	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D	SHR-A1403 Sensitive: D – Preclinical SHR-A1403 Sensitive : D